Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109994 | 0.96 | EBP (0.61) | EBPSIGMAR1HRH3SLC6A4LTA4H | |
| SCHEMBL7105837 | 0.95 | EBP (0.62) | EBPSIGMAR1HRH3LTA4H | |
| SCHEMBL3869661 | 0.92 | EBP (0.58) | EBPSIGMAR1HRH3KMT2ASLC6A4 | |
| SCHEMBL7108683 | 0.90 | EBP (0.59) | EBPSIGMAR1HRH3KDM4ELTA4H | |
| SCHEMBL7110375 | 0.90 | EBP (0.56) | EBPSIGMAR1HRH3SLC6A4LTA4H | |
| SCHEMBL7521111 | 0.89 | EBP (0.70) | EBPSIGMAR1HRH3LTA4H | |
| SCHEMBL3975634 | 0.88 | EBP (0.72) | EBPSIGMAR1HRH3LTA4H | |
| SCHEMBL13897766 | 0.87 | EBP (0.65) | EBPSIGMAR1HRH3LTA4H | |
| SCHEMBL7524285 | 0.87 | EBP (0.65) | EBPSIGMAR1HRH3LTA4H | |
| SCHEMBL13897747 | 0.86 | EBP (0.66) | EBPSIGMAR1HRH3ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | EBP 1842/4885SIGMAR1 1661/4885HRH3 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.